This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/drugbank/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/iuphar/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/guide-to-pharmacology/
n18http://bio2rdf.org/drugbank:
n31http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n7http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/chebi/
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n15http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n8http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00413/identifier/wikipedia/
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00413
rdf:type
n3:Drug
n3:description
Pramipexole is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist.
n3:dosage
n12:271B46F9-363D-11E5-9242-09173F13E4C5 n12:271B46FA-363D-11E5-9242-09173F13E4C5 n12:271B46FB-363D-11E5-9242-09173F13E4C5 n12:271B46FC-363D-11E5-9242-09173F13E4C5 n12:271B46FD-363D-11E5-9242-09173F13E4C5 n12:271B46FE-363D-11E5-9242-09173F13E4C5 n12:271B46FF-363D-11E5-9242-09173F13E4C5 n12:271B4700-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7664822
n3:group
investigational approved
n3:halfLife
8 hours
n3:indication
For the treatment of signs and symptoms of idiopathic Parkinson's disease
n3:manufacturer
n4:271B46D1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00413 n18:DB00413
dcterms:title
Pramipexole
adms:identifier
n20:Pramipexole n21:PA164742949 n24:953 n25:953 n26:DB00413 n27:50226040 n28:8356 n30:D00559 n31:0597-0183-90
n3:mechanismOfAction
The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
n3:packager
n4:271B46C7-363D-11E5-9242-09173F13E4C5 n4:271B46C8-363D-11E5-9242-09173F13E4C5 n4:271B46C5-363D-11E5-9242-09173F13E4C5 n4:271B46C6-363D-11E5-9242-09173F13E4C5 n4:271B46CC-363D-11E5-9242-09173F13E4C5 n4:271B46CB-363D-11E5-9242-09173F13E4C5 n4:271B46CD-363D-11E5-9242-09173F13E4C5 n4:271B46CE-363D-11E5-9242-09173F13E4C5 n4:271B46C9-363D-11E5-9242-09173F13E4C5 n4:271B46CA-363D-11E5-9242-09173F13E4C5 n4:271B46CF-363D-11E5-9242-09173F13E4C5 n4:271B46D0-363D-11E5-9242-09173F13E4C5 n4:271B46C3-363D-11E5-9242-09173F13E4C5 n4:271B46C4-363D-11E5-9242-09173F13E4C5 n4:271B46C2-363D-11E5-9242-09173F13E4C5
n3:patent
n23:6001861 n23:2275379 n23:4886812
n3:routeOfElimination
Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.
n3:synonym
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)- (-)-Pramipexole Pramipexol Pramipexolum (S)-Nā€Šā€Š6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Pramipexole
n3:volumeOfDistribution
* 500 L
n10:hasAHFSCode
n29:28-36-20-08
n3:foodInteraction
Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.
n3:proteinBinding
About 15% bound to plasma proteins.
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Pramipexole.htm
n13:hasConcept
n14:M0170120
foaf:page
n7:prampex.htm n8:mir1271.shtml n15:pramipexole.html
n3:IUPAC-Name
n5:271B4705-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B470B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B470A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4707-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4708-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4709-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4703-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B471B-363D-11E5-9242-09173F13E4C5 n5:271B4701-363D-11E5-9242-09173F13E4C5 n5:271B4704-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4702-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:N04BC05
n3:H-Bond-Acceptor-Count
n5:271B4711-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4712-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B470C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B470D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B470F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B470E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4710-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
104632-26-0
n3:category
n3:clearance
* renal cl=400 mL/min
n3:containedIn
n9:271B46D9-363D-11E5-9242-09173F13E4C5 n9:271B46DA-363D-11E5-9242-09173F13E4C5 n9:271B46DE-363D-11E5-9242-09173F13E4C5 n9:271B46DF-363D-11E5-9242-09173F13E4C5 n9:271B46DC-363D-11E5-9242-09173F13E4C5 n9:271B46DD-363D-11E5-9242-09173F13E4C5 n9:271B46E2-363D-11E5-9242-09173F13E4C5 n9:271B46E3-363D-11E5-9242-09173F13E4C5 n9:271B46E0-363D-11E5-9242-09173F13E4C5 n9:271B46E1-363D-11E5-9242-09173F13E4C5 n9:271B46D4-363D-11E5-9242-09173F13E4C5 n9:271B46D5-363D-11E5-9242-09173F13E4C5 n9:271B46D2-363D-11E5-9242-09173F13E4C5 n9:271B46D3-363D-11E5-9242-09173F13E4C5 n9:271B46D8-363D-11E5-9242-09173F13E4C5 n9:271B46DB-363D-11E5-9242-09173F13E4C5 n9:271B46D6-363D-11E5-9242-09173F13E4C5 n9:271B46D7-363D-11E5-9242-09173F13E4C5 n9:271B46EE-363D-11E5-9242-09173F13E4C5 n9:271B46F2-363D-11E5-9242-09173F13E4C5 n9:271B46EC-363D-11E5-9242-09173F13E4C5 n9:271B46ED-363D-11E5-9242-09173F13E4C5 n9:271B46F5-363D-11E5-9242-09173F13E4C5 n9:271B46F6-363D-11E5-9242-09173F13E4C5 n9:271B46F3-363D-11E5-9242-09173F13E4C5 n9:271B46F4-363D-11E5-9242-09173F13E4C5 n9:271B46E6-363D-11E5-9242-09173F13E4C5 n9:271B46E7-363D-11E5-9242-09173F13E4C5 n9:271B46E4-363D-11E5-9242-09173F13E4C5 n9:271B46E5-363D-11E5-9242-09173F13E4C5 n9:271B46EA-363D-11E5-9242-09173F13E4C5 n9:271B46EB-363D-11E5-9242-09173F13E4C5 n9:271B46E8-363D-11E5-9242-09173F13E4C5 n9:271B46E9-363D-11E5-9242-09173F13E4C5 n9:271B46F7-363D-11E5-9242-09173F13E4C5 n9:271B46F8-363D-11E5-9242-09173F13E4C5 n9:271B46F1-363D-11E5-9242-09173F13E4C5 n9:271B46EF-363D-11E5-9242-09173F13E4C5 n9:271B46F0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4717-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4719-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B471A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4716-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4715-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4718-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4706-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4713-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4714-363D-11E5-9242-09173F13E4C5